A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00482235
First received: June 1, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted
  Purpose

A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: MK0359
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: December 2002
  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • You are between the ages of 40 and 75
  • You have had a history for at least a year of COPD symptoms
  • You have a history of smoking one pack of cigarettes per day for 10 years

Exclusion Criteria:

  • You have been in a research study with an investigational drug or vaccine in the last 4 weeks.
  • You have donated blood in the last 4 weeks.
  • You have been hospitalized or had major surgery in the last 4 weeks
  • You have been treated in the emergency room within the last 2 months or hospitalized within the last 3 months for your COPD symptoms
  • You have a history of heart problems in the last 6 months
  • You have a history of stomach problems
  • You are unwilling to avoid grapefruit juice throughout the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00482235

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00482235     History of Changes
Other Study ID Numbers: 2007_569
Study First Received: June 1, 2007
Last Updated: June 1, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Lung Diseases
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on September 16, 2014